WO1997001640A3 - Vaccines against hepatitis c - Google Patents
Vaccines against hepatitis c Download PDFInfo
- Publication number
- WO1997001640A3 WO1997001640A3 PCT/EP1996/002764 EP9602764W WO9701640A3 WO 1997001640 A3 WO1997001640 A3 WO 1997001640A3 EP 9602764 W EP9602764 W EP 9602764W WO 9701640 A3 WO9701640 A3 WO 9701640A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- hepatitis
- vaccines against
- against hepatitis
- water emulsion
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000007764 o/w emulsion Substances 0.000 abstract 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 229940087168 alpha tocopherol Drugs 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 235000004835 α-tocopherol Nutrition 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9609258A BR9609258A (en) | 1995-06-29 | 1996-06-20 | Hepatitis C vaccines |
AU63049/96A AU6304996A (en) | 1995-06-29 | 1996-06-20 | Vaccines against hepatitis c |
EP96922029A EP0835318A2 (en) | 1995-06-29 | 1996-06-20 | Vaccines against hepatitis c |
JP9504167A JPH11508769A (en) | 1995-06-29 | 1996-06-20 | Vaccine against hepatitis C |
PL96324906A PL324906A1 (en) | 1995-06-29 | 1996-06-20 | Vaccines against viral hepatitis of c type |
NO976060A NO976060L (en) | 1995-06-29 | 1997-12-23 | Vaccines against hepatitis C |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9513261.9A GB9513261D0 (en) | 1995-06-29 | 1995-06-29 | Vaccines |
GB9513261.9 | 1995-06-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997001640A2 WO1997001640A2 (en) | 1997-01-16 |
WO1997001640A3 true WO1997001640A3 (en) | 1997-05-15 |
Family
ID=10776867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/002764 WO1997001640A2 (en) | 1995-06-29 | 1996-06-20 | Vaccines against hepatitis c |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0835318A2 (en) |
JP (1) | JPH11508769A (en) |
KR (1) | KR19990028505A (en) |
AU (1) | AU6304996A (en) |
BR (1) | BR9609258A (en) |
CA (1) | CA2222456A1 (en) |
CZ (1) | CZ422397A3 (en) |
GB (1) | GB9513261D0 (en) |
HU (1) | HUP9901901A3 (en) |
IL (1) | IL122589A0 (en) |
NO (1) | NO976060L (en) |
PL (1) | PL324906A1 (en) |
TR (1) | TR199701713T1 (en) |
WO (1) | WO1997001640A2 (en) |
ZA (1) | ZA965459B (en) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0909323B1 (en) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Helicobacter pylori bacterioferritin |
US5858389A (en) * | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
AT405939B (en) * | 1997-02-24 | 1999-12-27 | Immuno Ag | METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
GB9712347D0 (en) * | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
US6685944B1 (en) * | 1998-08-21 | 2004-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified HCV peptide vaccines |
TR200101055T2 (en) | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvant systems and vaccines |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
AU772617B2 (en) * | 1999-11-19 | 2004-05-06 | Csl Limited | Vaccine compositions |
AU2002214127B2 (en) | 2000-10-27 | 2007-06-07 | J. Craig Venter Institute, Inc. | Nucleic acids and proteins from streptococcus groups A and B |
WO2002046477A2 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
AU2002249253A1 (en) * | 2002-03-04 | 2002-07-08 | Zagyansky, Yuly | Universal antimicrobial treatment |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
BRPI0315228A8 (en) | 2002-10-11 | 2018-04-03 | Chiron Srl | Polypeptide vaccines for broad protection against hypervirulent meningococcal strains |
AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
EP2172213B1 (en) | 2003-01-30 | 2013-04-03 | Novartis AG | Injectable vaccines against multiple meningococcal serogroups |
ES2423800T3 (en) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
EP2179729B1 (en) | 2003-06-02 | 2016-07-20 | GlaxoSmithKline Biologicals SA | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
WO2005032583A2 (en) | 2003-10-02 | 2005-04-14 | Chiron Srl | Liquid vaccines for multiple meningococcal serogroups |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
PL1740217T3 (en) | 2004-04-30 | 2012-03-30 | Novartis Ag | Meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
JP4896021B2 (en) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Alphavirus vector for respiratory pathogen vaccine |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
US20060165716A1 (en) | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
CA2590974C (en) | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
PL2351772T3 (en) | 2005-02-18 | 2017-01-31 | Glaxosmithkline Biologicals Sa | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
WO2006091517A2 (en) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics Inc. | Immunogens from uropathogenic escherichia coli |
EP2357000A1 (en) | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
ATE539079T1 (en) | 2006-03-23 | 2012-01-15 | Novartis Ag | IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS |
EP2054431B1 (en) | 2006-06-09 | 2011-08-31 | Novartis AG | Conformers of bacterial adhesins |
AU2007285484B2 (en) | 2006-08-16 | 2013-05-02 | Novartis Ag | Immunogens from uropathogenic Escherichia coli |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
ES2561483T3 (en) | 2007-09-12 | 2016-02-26 | Glaxosmithkline Biologicals Sa | GAS57 mutant antigens and GAS57 antibodies |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
BRPI0821240B8 (en) | 2007-12-21 | 2022-10-04 | Novartis Ag | mutant forms of streptolysin o |
EP2245048B1 (en) | 2008-02-21 | 2014-12-31 | Novartis AG | Meningococcal fhbp polypeptides |
WO2009114485A2 (en) | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
EP2376108B1 (en) | 2008-12-09 | 2017-02-22 | Pfizer Vaccines LLC | IgE CH3 PEPTIDE VACCINE |
NZ594029A (en) | 2009-01-12 | 2014-01-31 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
AU2010238255B2 (en) | 2009-04-14 | 2014-10-16 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
EP2424562B1 (en) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
CN102802665B (en) | 2009-06-15 | 2015-11-25 | 新加坡国立大学 | Influenza vaccines, compositions and using method |
MX2012000395A (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens. |
CA2768343A1 (en) | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
NZ618391A (en) | 2009-07-30 | 2015-07-31 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
CN102596240B (en) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | Hybrid polypeptides including meningococcal fHBP sequences |
CN102612558B (en) | 2009-09-03 | 2015-02-11 | 辉瑞疫苗有限责任公司 | Pcsk9 vaccine |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
MY157607A (en) * | 2009-09-10 | 2016-06-30 | Merial Inc | New vaccine formulations comprising saponin-containing adjuvants |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
BR112012009014B8 (en) | 2009-09-30 | 2022-10-04 | Novartis Ag | PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION |
WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
MX2012004850A (en) | 2009-10-27 | 2012-05-22 | Novartis Ag | Modified meningococcal fhbp polypeptides. |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP6007105B2 (en) | 2009-12-22 | 2016-10-12 | セルデックス・セラピューティクス・インコーポレイテッド | Vaccine composition |
US9173954B2 (en) | 2009-12-30 | 2015-11-03 | Glaxosmithkline Biologicals Sa | Polysaccharide immunogens conjugated to E. coli carrier proteins |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
CN110845585A (en) | 2010-03-30 | 2020-02-28 | 奥克兰儿童医院及研究中心 | Modified Factor H Binding Proteins (FHBP) and methods of use thereof |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
EP2575988A1 (en) | 2010-05-28 | 2013-04-10 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
CA2798837A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
WO2012006293A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
NZ611176A (en) | 2010-12-02 | 2015-07-31 | Bionor Immuno As | Peptide scaffold design |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
JP6294076B2 (en) | 2011-01-06 | 2018-03-14 | ビオノール イミュノ エーエスBionor Immuno As | Multimeric peptide |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
US10030052B2 (en) | 2011-07-25 | 2018-07-24 | Glaxosmithkline Biologicals Sa | Parvovirus Vp1 unique region polypeptides and compositions thereof |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
ES2732708T3 (en) | 2011-09-14 | 2019-11-25 | Glaxosmithkline Biologicals Sa | Manufacturing procedures of saccharide-protein glucoconjugates |
WO2013038385A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Escherichia coli vaccine combination |
CA2858519A1 (en) | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
JP2015509713A (en) | 2012-02-24 | 2015-04-02 | ノバルティス アーゲー | Pili protein and composition |
US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
WO2013160335A2 (en) | 2012-04-26 | 2013-10-31 | Novartis Ag | Antigens and antigen combinations |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659908A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
PL2844282T3 (en) | 2012-05-04 | 2019-11-29 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
CA2874210A1 (en) | 2012-05-22 | 2013-11-28 | Novartis Ag | Meningococcus serogroup x conjugate |
US10501499B2 (en) | 2012-06-06 | 2019-12-10 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
EP2897635A1 (en) | 2012-09-18 | 2015-07-29 | Novartis AG | Outer membrane vesicles |
CN105307684A (en) | 2012-10-02 | 2016-02-03 | 葛兰素史密丝克莱恩生物有限公司 | Nonlinear saccharide conjugates |
CN104582718B (en) | 2012-10-03 | 2017-10-24 | 诺华股份有限公司 | Immunogenic composition |
PL2925355T3 (en) | 2012-11-30 | 2018-06-29 | Glaxosmithkline Biologicals S.A. | Pseudomonas antigens and antigen combinations |
CN112999344A (en) | 2013-05-15 | 2021-06-22 | 阿尔伯达大学董事会 | E1E2HCV vaccine and methods of use |
NZ755769A (en) | 2014-01-21 | 2023-06-30 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
US10266572B2 (en) | 2014-07-23 | 2019-04-23 | Children's Hospital & Research Center At Oakland | Factor H binding protein variants and methods of use thereof |
HRP20230416T1 (en) | 2015-01-15 | 2023-07-07 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US10576131B2 (en) | 2015-06-03 | 2020-03-03 | Affiris Ag | IL-23-p19 vaccines |
EP3319988A1 (en) | 2015-07-07 | 2018-05-16 | Affiris AG | Vaccines for the treatment and prevention of ige mediated diseases |
EP3325008A1 (en) | 2015-07-21 | 2018-05-30 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
HUE051722T2 (en) | 2016-01-19 | 2021-03-29 | Pfizer | Cancer vaccines |
CA3050622A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
CA3109889A1 (en) | 2018-08-23 | 2020-02-27 | Glaxosmithkline Biologicals Sa | Immunogenic proteins and compositions |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
EP3893926A1 (en) | 2018-12-12 | 2021-10-20 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
JP7239509B6 (en) | 2019-02-22 | 2023-03-28 | ファイザー・インク | Method for purifying bacterial polysaccharides |
US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
JP2021087420A (en) | 2019-11-01 | 2021-06-10 | ファイザー・インク | Escherichia coli compositions and methods thereof |
US20220380769A1 (en) | 2020-01-24 | 2022-12-01 | Aim Immunotech Inc. | Methods, compositions, and vaccines for treating a virus infection |
EP4103587A1 (en) | 2020-02-14 | 2022-12-21 | Immunor AS | Corona virus vaccine |
IL295713A (en) | 2020-02-21 | 2022-10-01 | Pfizer | Purification of saccharides |
WO2021165928A2 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
IL302362A (en) | 2020-10-27 | 2023-06-01 | Pfizer | Escherichia coli compositions and methods thereof |
CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
JP2023549736A (en) | 2020-11-10 | 2023-11-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
IL305313A (en) | 2021-02-19 | 2023-10-01 | Sanofi Pasteur | Meningococcal b recombinant vaccine |
AU2022281543A1 (en) | 2021-05-28 | 2023-11-23 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
TW202306969A (en) | 2021-05-28 | 2023-02-16 | 美商輝瑞大藥廠 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023092090A1 (en) | 2021-11-18 | 2023-05-25 | Matrivax, Inc. | Immunogenic fusion protein compositions and methods of use thereof |
WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472207A2 (en) * | 1990-08-24 | 1992-02-26 | Abbott Laboratories | Hepatitis C assay utilizing recombinant antigens |
DE4041304A1 (en) * | 1990-12-21 | 1992-06-25 | Mikrogen Molekularbiol Entw | POLYPEPTIDES DERIVED FROM STRUCTURAL PROTEINS OF HEPATITIS C-VIRUS, TEST KITS CONTAINING THESE POLYPEPTIDES AND VACCINE AGAINST INFECTIONS FROM HEPATITIS C VIRUSES |
WO1993000365A2 (en) * | 1991-06-24 | 1993-01-07 | Chiron Corporation | Hepatitis c virus (hcv) polypeptides |
WO1993019780A1 (en) * | 1992-03-27 | 1993-10-14 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
WO1994000153A1 (en) * | 1992-06-25 | 1994-01-06 | Smithkline Beecham Biologicals (S.A.) | Vaccine composition containing adjuvants |
JPH06279500A (en) * | 1992-09-30 | 1994-10-04 | Imuno Japan:Kk | Hbc fused protein particle and its production |
WO1995017210A1 (en) * | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
-
1995
- 1995-06-29 GB GBGB9513261.9A patent/GB9513261D0/en active Pending
-
1996
- 1996-06-20 KR KR1019970709823A patent/KR19990028505A/en not_active Application Discontinuation
- 1996-06-20 AU AU63049/96A patent/AU6304996A/en not_active Abandoned
- 1996-06-20 HU HU9901901A patent/HUP9901901A3/en unknown
- 1996-06-20 CZ CZ974223A patent/CZ422397A3/en unknown
- 1996-06-20 EP EP96922029A patent/EP0835318A2/en not_active Withdrawn
- 1996-06-20 WO PCT/EP1996/002764 patent/WO1997001640A2/en not_active Application Discontinuation
- 1996-06-20 TR TR97/01713T patent/TR199701713T1/en unknown
- 1996-06-20 CA CA002222456A patent/CA2222456A1/en not_active Abandoned
- 1996-06-20 BR BR9609258A patent/BR9609258A/en unknown
- 1996-06-20 IL IL12258996A patent/IL122589A0/en unknown
- 1996-06-20 PL PL96324906A patent/PL324906A1/en unknown
- 1996-06-20 JP JP9504167A patent/JPH11508769A/en active Pending
- 1996-06-27 ZA ZA965459A patent/ZA965459B/en unknown
-
1997
- 1997-12-23 NO NO976060A patent/NO976060L/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472207A2 (en) * | 1990-08-24 | 1992-02-26 | Abbott Laboratories | Hepatitis C assay utilizing recombinant antigens |
DE4041304A1 (en) * | 1990-12-21 | 1992-06-25 | Mikrogen Molekularbiol Entw | POLYPEPTIDES DERIVED FROM STRUCTURAL PROTEINS OF HEPATITIS C-VIRUS, TEST KITS CONTAINING THESE POLYPEPTIDES AND VACCINE AGAINST INFECTIONS FROM HEPATITIS C VIRUSES |
WO1993000365A2 (en) * | 1991-06-24 | 1993-01-07 | Chiron Corporation | Hepatitis c virus (hcv) polypeptides |
WO1993019780A1 (en) * | 1992-03-27 | 1993-10-14 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
WO1994000153A1 (en) * | 1992-06-25 | 1994-01-06 | Smithkline Beecham Biologicals (S.A.) | Vaccine composition containing adjuvants |
JPH06279500A (en) * | 1992-09-30 | 1994-10-04 | Imuno Japan:Kk | Hbc fused protein particle and its production |
WO1995017210A1 (en) * | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
WO1995017209A1 (en) * | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 9444, Derwent World Patents Index; Class B04, AN 94-354772, XP002028489 * |
Also Published As
Publication number | Publication date |
---|---|
NO976060D0 (en) | 1997-12-23 |
GB9513261D0 (en) | 1995-09-06 |
NO976060L (en) | 1998-02-17 |
TR199701713T1 (en) | 1998-05-21 |
IL122589A0 (en) | 1998-06-15 |
ZA965459B (en) | 1997-04-01 |
AU6304996A (en) | 1997-01-30 |
JPH11508769A (en) | 1999-08-03 |
KR19990028505A (en) | 1999-04-15 |
CZ422397A3 (en) | 1998-06-17 |
WO1997001640A2 (en) | 1997-01-16 |
PL324906A1 (en) | 1998-06-22 |
HUP9901901A2 (en) | 1999-09-28 |
MX9710523A (en) | 1998-09-30 |
HUP9901901A3 (en) | 2000-03-28 |
EP0835318A2 (en) | 1998-04-15 |
BR9609258A (en) | 1999-05-11 |
CA2222456A1 (en) | 1997-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997001640A3 (en) | Vaccines against hepatitis c | |
CA2302554A1 (en) | Oil in water emulsions containing saponins | |
CA2217178A1 (en) | Vaccines containing a saponin and a sterol | |
HUP9903169A3 (en) | Low pathogenicity prrs live virus vaccines and methods of preparation thereof | |
GB2303855B (en) | Helicobacter pylori antigenic protein preparation and immunoassays | |
EP1946773A3 (en) | Improved saponin adjuvant compositions and methods relating thereto | |
AU6803298A (en) | Vaccines | |
EP1170016A3 (en) | Urease-based vaccine against helicobacter infection | |
CA2132547A1 (en) | Vaccines Containing Non-Ionic Surfactant Vesicles | |
AU6093296A (en) | Infectious dengue 2 virus pdk-53 as quadravalent vaccine | |
EP0745387A3 (en) | Adjuvants for viral vaccines | |
AU4195897A (en) | Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof | |
ZA936629B (en) | Potentiation of immunogenic response | |
DK0792165T3 (en) | Immunogenic Preparations | |
NO912825D0 (en) | PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IMMUNOGENIC PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS. | |
DE3473825D1 (en) | Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained | |
CA2190344A1 (en) | Quillaja saponin adjuvant and vaccine formulation containing same | |
CA2099707A1 (en) | Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins | |
CA2352563A1 (en) | Method to produce inactivated w/o emulsion adjuvanted vaccines | |
AU1631188A (en) | Newcastle disease virus vaccine and method for the application thereof | |
WO2002038176A3 (en) | Immunogenic compositions comprising liver stage malarial antigens | |
WO2002009749A3 (en) | Respiratory syncytial virus vaccine | |
WO2000069458A3 (en) | Adjuvant combinations for immunization composition and vaccines | |
CA2112225A1 (en) | Attenuated revertant serotype 1 marek's disease vaccine | |
WO2002024147A3 (en) | Avian pneumovirus vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96195150.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 311683 Country of ref document: NZ |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996922029 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2222456 Country of ref document: CA Ref document number: 2222456 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/010523 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 504167 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 97/01713 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970709823 Country of ref document: KR Ref document number: PV1997-4223 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996922029 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-4223 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970709823 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-4223 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996922029 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970709823 Country of ref document: KR |